Meglumine antimoniate

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Meglumine antimoniate
Meglumine antimoniate major component 3D.png
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
ATC code
Identifiers
Synonyms meglumine antimonate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
NIAID ChemDB
ECHA InfoCard 100.004.645
Chemical and physical data
Formula Variable
Molar mass Variable
3D model (Jmol)
 NYesY (what is this?)  (verify)

Meglumine antimoniate is a medicine used to leishmaniasis. This include visceral, mucocutaneous, and cutaneous leishmaniasis. It is given by injection into a muscle or into the area infected.[1]

Side effects include loss of appetite, nausea, abdominal pain, cough, feeling tired, muscle pains, irregular heartbeat, and kidney problems. It should not be used in people with significant heart, liver, or kidney problems. It is not recommended during breastfeeding. It belongs to a group of medications known as the pentavalent antimonials.[1]

Meglumine antimoniate came into medical use in 1946.[2] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[3] The wholesale cost in the developing world is about 4.32 USD per vial as of 2014.[4] It is available in Southern Europe and Latin America but not the United States.[5][6]

Society and culture[edit]

It is manufactured by Aventis[7] and sold as Glucantime in France, and Glucantim in Italy.

See also[edit]

References[edit]

  1. ^ a b WHO Model Formulary 2008 (PDF). World Health Organization. 2009. p. 183. ISBN 9789241547659. Retrieved 8 December 2016. 
  2. ^ Sneader, Walter (2005). Drug Discovery: A History. John Wiley & Sons. p. 59. ISBN 9780470015520. 
  3. ^ "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016. 
  4. ^ "Meglumine Antimonate". International Drug Price Indicator Guide. Retrieved 8 December 2016. 
  5. ^ Bope, Edward T.; Kellerman, Rick D.; Rakel, Robert E. (2010). Conn's Current Therapy 2011: Expert Consult. Elsevier Health Sciences. p. 95. ISBN 143773572X. 
  6. ^ Gorbach, Sherwood L.; Bartlett, John G.; Blacklow, Neil R. (2004). Infectious Diseases. Lippincott Williams & Wilkins. p. 355. ISBN 9780781733717. 
  7. ^ Aventis press release, 15 April 2005. (German)